HPLC Analysis in Peptide Quality Control

Compiled by the APL Research TeamSourced directly from peer-reviewed pharmacological literature and clinical guidelines.

Key Takeaways

• Expert Insight: A detailed guide to HPLC methods used in peptide purity testing, covering reverse-phase chromatography principles, interpreting chromatograms, and understanding purity specifications.
• Quality Assurance: All discussed methodologies align with stringent Australian laboratory standards.
• Clinical Relevance: Critical informational resource for verifying the stability and purity of hplc analysis in peptide quality control in-vitro.

Introduction

High-Performance Liquid Chromatography (HPLC) is the gold standard analytical method for assessing peptide purity. Every Certificate of Analysis (CoA) for a research peptide includes HPLC purity data, and understanding how this data is generated and what it means is essential for evaluating peptide quality and designing reliable experiments.

This guide covers the principles of reverse-phase HPLC as applied to peptide analysis, how to interpret chromatograms, and what the purity numbers on a CoA actually represent.

Principles of Reverse-Phase HPLC

How It Works

Reverse-phase HPLC separates molecules based on their hydrophobicity (affinity for nonpolar surfaces):

1. Sample injection — a small volume of the peptide solution is injected into the HPLC system
2. Column separation — the sample passes through a column packed with C18-bonded silica particles (the stationary phase)
3. Gradient elution — a mobile phase gradient (increasing organic solvent concentration) is applied, progressively eluting compounds from least hydrophobic to most hydrophobic
4. Detection — a UV detector (typically at 214 nm, where the peptide bond absorbs strongly) records the signal as compounds elute
5. Chromatogram — the detector output is plotted as absorbance vs. time, producing peaks for each resolved component

Why 214 nm?

The peptide bond (amide bond) has a strong UV absorption at approximately 214 nm. This wavelength provides:

• Universal detection — all peptides absorb at this wavelength, regardless of their amino acid composition
• High sensitivity — the molar absorptivity of the amide bond is high, allowing detection of nanogram quantities
• Proportional response — for peptides of similar length, the UV response is roughly proportional to mass, making area-percent calculations meaningful

Alternative wavelengths (220 nm, 254 nm, 280 nm) may be used for specific applications, but 214 nm is the standard for purity assessment.

A certificate should tell you which channel its purity figure came from, because the number is not comparable across wavelengths. Ours name it on the chromatogram — PDA 214 nm on every batch in the certificate library.

Mobile Phase

The standard mobile phase system for peptide HPLC:

• Solvent A: Water + 0.1% TFA (trifluoroacetic acid)
• Solvent B: Acetonitrile + 0.1% TFA

TFA serves as an ion-pairing agent — it associates with positively charged groups on the peptide, reducing peak tailing and improving chromatographic resolution. The gradient typically runs from 5-10% B to 60-90% B over 20-40 minutes.

Reading a Chromatogram

The Main Peak

The largest peak on the chromatogram represents the target peptide. Key characteristics:

• Retention time (tR): The time at which the peptide elutes from the column. This is characteristic of the peptide's hydrophobicity under the specific method conditions.
• Peak shape: An ideal peak is sharp, symmetrical, and Gaussian. Peak broadening, tailing, or shouldering may indicate impurities co-eluting with the target or column degradation.
• Peak area: Proportional to the amount of peptide detected. The ratio of the main peak area to the total peak area gives the HPLC purity percentage.

Impurity Peaks

Peaks other than the main peak represent impurities:

• Earlier-eluting peaks (lower retention time) — more hydrophilic than the target. Often deletion sequences (shorter peptides), deamidation products (additional negative charge), or truncation products.
• Later-eluting peaks (higher retention time) — more hydrophobic than the target. May include aggregated forms, peptides with incomplete side-chain deprotection, or oxidation products of certain residues.
• Peak clusters — multiple closely-spaced peaks may indicate a family of related impurities (e.g., several different deletion sequences).

Calculating Purity

HPLC purity is calculated by area normalisation:

Purity (%) = (Area of main peak / Total area of all peaks) × 100

For example, if the main peak has an area of 980,000 and all other peaks sum to 20,000: Purity = (980,000 / 1,000,000) × 100 = 98.0%

A Measured Example

The chromatogram published for BPC-157 batch APL-BPC10-2608-03 was run on a PDA detector at 214 nm and integrates five peaks:

Total integrated area is 7,200,000, so area normalisation gives 7,136,640 / 7,200,000 × 100 = 99.12% — the figure printed on the certificate.

Two things in that table are worth more than the headline number. The area percentages sum to exactly 100%, which they must; a published peak list that does not close has had something dropped from it. And the largest impurity sits at 3.08 minutes, just 0.16 minutes ahead of the main peak — close enough that a steeper gradient would likely have merged the two and reported a higher purity from a worse separation. This is what the method-dependence described below looks like in practice, and it is why the trace matters more than the percentage derived from it.

Common Impurities and Their Chromatographic Behaviour

Method Parameters That Affect Results

HPLC purity values are method-dependent — the same sample can give different purity numbers under different conditions:

Column Selection

• C18 columns — standard for most peptides, providing good resolution of hydrophobic differences
• C8 columns — less hydrophobic stationary phase, useful for very hydrophobic peptides that bind too strongly to C18
• C4 columns — used for larger peptides and small proteins
• Particle size — smaller particles (1.7-3 μm) provide higher resolution but require higher pressures (UHPLC)

Gradient Conditions

• Steeper gradients — faster analysis but lower resolution; impurity peaks may not separate from the main peak
• Shallower gradients — better resolution but longer run times; important for closely-related impurities
• Gradient range — must be optimised for the peptide's elution window

Temperature

• Higher column temperatures generally improve peak shape and resolution
• Typical range: 25-60°C
• Temperature affects selectivity — some impurities that co-elute at one temperature may separate at another

Limitations of HPLC Purity

HPLC is powerful but not infallible. Important limitations to understand:

Co-Elution

If an impurity has the same hydrophobicity as the target peptide, it will elute at the same retention time and inflate the apparent purity. Common co-eluting species include:

• D-amino acid substitutions (diastereomers with very similar hydrophobicity)
• Isoaspartate formation (similar hydrophobicity to the native Asp-containing peptide)
• TFA/acetate salt form differences

Non-Peptide Impurities

UV detection at 214 nm is sensitive to all UV-absorbing species, not just peptides. Residual reagents, solvents, or buffer components may produce peaks that are incorrectly counted as peptide impurities (or may not absorb at 214 nm and be missed entirely).

Peptide Content vs. Purity

HPLC purity tells you the proportion of peptide that is the correct sequence. It does not tell you the proportion of the total powder that is peptide. A sample can be 98% pure by HPLC but have only 70% peptide content — the remaining 30% being counter-ions (TFA, acetate), water, and non-UV-absorbing salts.

Orthogonal Analytical Methods

To get a complete picture of peptide quality, HPLC is complemented by:

• Mass spectrometry (MS) — confirms molecular identity; detects impurities by mass even if they co-elute on HPLC
• Chiral HPLC — separates D- and L-amino acid-containing diastereomers that standard RP-HPLC cannot resolve
• Ion-exchange HPLC — separates based on charge rather than hydrophobicity, providing an orthogonal separation dimension
• Capillary electrophoresis — separates based on charge-to-size ratio, complementary to HPLC

For a comprehensive guide to interpreting all CoA data, see our article on Understanding Certificates of Analysis.

Practical Implications for Research

Selecting the Right Purity Grade

• >98% purity: Recommended for quantitative dose-response studies, binding assays, and any experiment where precise peptide concentration is critical
• 95-98% purity: Suitable for most screening experiments, preliminary studies, and in-vivo research
• 90-95% purity: Acceptable for initial feasibility studies and method development

Accounting for Impurities

When comparing results across batches or between laboratories:

1. Always note the HPLC purity of the material used
2. Consider whether impurities could produce biological activity (a 5% impurity that is a biologically active deletion sequence is more problematic than 5% of an inactive truncation product)
3. For critical experiments, verify purity independently using your own HPLC system

Failing that, insist on seeing the trace. A supplier that publishes only a purity percentage is asking you to accept an integration you cannot inspect; one that publishes the chromatogram and the peak list is showing its working. Every batch we release does the latter in the certificate library, and each compound's page — all BPC-157 batches, for example — collects every batch we have published so the traces can be compared over time rather than one at a time.

References

1. Mant, C.T. & Hodges, R.S "HPLC of Peptides and Proteins: Methods and Protocols." Methods in Molecular Biology, vol. 251. — View source
2. Snyder, L.R. et al. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley, 2010. — View source
3. Huo Y et al. "Characterization of structurally related peptide impurities using HPLC-QTOF-MS/MS: application to Cbf-14, a novel antimicrobial peptide." Analytical and Bioanalytical Chemistry, 2022. — PubMed: 35840670
4. Strege MA et al. "Enantiomeric purity analysis of synthetic peptide therapeutics by direct chiral high-performance liquid chromatography-electrospray ionization tandem mass spectrometry." Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 2023. — PubMed: 36857849

⚠️ Medical & Regulatory Disclaimer:
The information provided in this academic article is intended exclusively for educational and laboratory research purposes. It does NOT constitute medical advice. Compounds discussed are strictly for in-vitro research and development only, and are not intended for human consumption, veterinary use, or clinical treatment. Always adhere to Australian Therapeutic Goods Administration (TGA) regulations and your institution's ethical guidelines when handling research chemicals.